Caron A Jacobson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Caron A Jacobson

Showing results (51-60 of 140) with videos related to

Pageof 14

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2025

Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 TrialCaron A Jacobson, Jason R Westin, David B Miklos, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2020

Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell LymphomaShruti Gupta, Harish Seethapathy, Ian A Strohbehn, et al.

Blood|March 18, 2020

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Olalekan O Oluwole, et al.

The Oncologist|December 30, 2017

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and AnalysisLova Sun, Shuli Li, Areej El-Jawahri, et al.

Transplantation and Cellular Therapy|March 11, 2023

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy RecipientsMuneerah M Aleissa, Jessica S Little, Sonya Davey, et al.

Haematologica|June 1, 2023

Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L Crombie, Caron A Jacobson, Robert Redd, et al.

Clinical Lymphoma, Myeloma & Leukemia|January 12, 2021

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisStephen D Smith, Paolo Lopedote, Yazeed Samara, et al.

Journal for Immunotherapy of Cancer|November 30, 2022

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapyYalda Amidi, Christine A Eckhardt, Syed A Quadri, et al.

Clinical Lymphoma, Myeloma & Leukemia|February 16, 2024

A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular LymphomaPaola Ghione, M Lia Palomba, Markqayne D Ray, et al.

Leukemia & Lymphoma|March 26, 2025

A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomasMwanasha H Merrill, Robert A Redd, David C Fisher, et al.

Pageof 14

Search research articles

Showing results (51-60 of 140) with videos related to

Sort By:

Pageof 14

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2025

Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 TrialCaron A Jacobson, Jason R Westin, David B Miklos, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2020

Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell LymphomaShruti Gupta, Harish Seethapathy, Ian A Strohbehn, et al.

Blood|March 18, 2020

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Olalekan O Oluwole, et al.

The Oncologist|December 30, 2017

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and AnalysisLova Sun, Shuli Li, Areej El-Jawahri, et al.

Transplantation and Cellular Therapy|March 11, 2023

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy RecipientsMuneerah M Aleissa, Jessica S Little, Sonya Davey, et al.

Haematologica|June 1, 2023

Clinical Lymphoma, Myeloma & Leukemia|January 12, 2021

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisStephen D Smith, Paolo Lopedote, Yazeed Samara, et al.

Journal for Immunotherapy of Cancer|November 30, 2022

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapyYalda Amidi, Christine A Eckhardt, Syed A Quadri, et al.

Clinical Lymphoma, Myeloma & Leukemia|February 16, 2024

A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular LymphomaPaola Ghione, M Lia Palomba, Markqayne D Ray, et al.

Leukemia & Lymphoma|March 26, 2025

A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomasMwanasha H Merrill, Robert A Redd, David C Fisher, et al.

Pageof 14